Sarepta (SRPT) Therapeutics announced that the rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the U.S. Food & Drug Administration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta management to meet with Oppenheimer
- Optimistic Outlook for Sarepta Therapeutics Amid Positive Developments in ENVISION Study and Strategic Partnerships
- Sarepta Therapeutics: Navigating Clinical Holds and Regulatory Challenges Amidst Market Expansion Uncertainty
- Target slides after cutting sales forecast: Morning Buzz
- Sarepta jumps 5% to $42.11 after UK allows Elevidys study to continue